TITLE:
Skeletal muscle and whole body insulin resistance but not cardiac muscle insulin resistance could be improved by troglitazone therapy within 12 weeks in type-2 diabetes
AUTHORS:
Ikuo Yokoyama, Toshiyuki Moritan, Yusuke Inoue
KEYWORDS:
Insulin Resistance; Myocardial Insulin Resistance; Glucose Metabolism; Skeletal Muscle; Type II Diabetes Mellitus; 18F-FDG; PET
JOURNAL NAME:
Journal of Biomedical Science and Engineering,
Vol.5 No.12A,
December
31,
2012
ABSTRACT: Background: Existence of myocardial insulin resistance
(IR) has been reported in type II diabetics (T2- DM) and coronary artery
disease (CAD). Improvement in heart and skeletal muscle IR after thiazolidinedione’s
therapy was reported in T2DM and CAD. However effects of troglitazone therapy
(TRO) on myocardial IR remain uncertain. To clarify heart and skeletal muscle
and whole body IR in T2DM without CAD by TRO to clarify whether TRO would
provide different results. Methods: We analyzed data on 15 T2DM patients who
underwent dynamic PET with 18F-FDG under insulin clamping before and
during TRO (200 mg/day) and 17 controls. Results: Whole body glucose disposal
rate (WBGR mg/min/kg) in T2DM before TRO (3.41 ± 1.72) was significantly lower
than in controls (9.76 ± 2.97, p